Thailand Medical Device Registration: How Are Authorized Representative Responsibilities Divided?

Answer: In Thailand, the responsibilities of an authorized representative are not limited to submitting documents. They typically include local communication with the Thai FDA, dossier submission and deficiency responses, coordination with importers, labeling and instructions-for-use localization, certificate control, change notifications, renewal maintenance, and post-market event handling. The manufacturer, authorized representative, importer, and registration holder should define these duties in a written agreement because the allocation directly affects certificate ownership, market control, and long-term compliance.

Published: 2026-07-10 12:29 Updated: 2026-07-10 12:29

This FAQ examines priority questions that companies must address in actual international medical device registration projects, covering dossier preparation, compliance pathways, and post-market maintenance.

Contents

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Assessment Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Continue Reading
• Scope and Applicability

Key Summary

Medical device registration in Thailand usually requires confirmation of product classification and the applicable pathway before preparing technical files, labels and instructions for use, quality system evidence, authorization documents, and local representative information. Existing NMPA documentation can serve as a basis, but it usually must be adapted to Thai FDA requirements in terms of language, format, labeling, and evidence chain.

For Chinese medical device companies, a prudent approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Thailand registration often affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If a project is advanced only by asking which documents to submit, deficiencies or rework are likely in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies plan this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

Companies should also make project-specific judgments based on the latest requirements of the target country regulator, the existing technical file basis, the product risk classification, and the launch plan, avoiding mechanical preparation based only on a document checklist.

Compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be subject to the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for how authorized representative responsibilities are divided for medical device registration in Thailand usually want to determine whether existing documentation can support a Thai submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect the launch plan. Behind this question are often product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the intended use, mechanism of action, use scenario, method of body contact, duration of use, whether the device is sterile, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. Once the pathway is wrongly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For a Thailand project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control may be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions-for-use claims, model coverage of test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulators focus on whether the device is safe, effective, and traceable for the intended use, not on whether the company uploaded a large number of documents.

Common Errors

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating domestic NMPA documentation and submitting it without rearranging the evidence according to the Thai pathway.
• Including too many models and specifications while test reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistency among labels, instructions for use, promotional materials, and registration dossier claims, leading to deficiency responses or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, which increases cost and timelines because each country requires separate preparation.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation basis and avoid discovering critical evidence gaps only after submission.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management files, clinical evaluations, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table identifying content that needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Thailand registration as a one-time document submission but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents country by country at short notice.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still face repeated issues during deficiency responses, agent communication, and post-market maintenance, even if the documentation appears extensive.

Common Follow-up Questions

Can domestic documentation be used directly for Thailand registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model specifications, or instructions-for-use version differs from the test reports, the company may be required to provide supplementary explanations even if it has prepared a large volume of documents.

Before submission, companies should establish an evidence consistency checklist that matches product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions-for-use version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency responses, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product series.

Localization Conversion and Agent Responsibilities

Thailand registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot simply be translated. Companies should verify local language requirements, boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining certificates but neglect post-market maintenance. If a manufacturing site change, model expansion, instructions-for-use update, or agent replacement occurs later, the certificate and market sales can easily become disconnected.

AIMEILI recommends that companies manage this question within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country but also enabling the company to build replicable overseas compliance capability and reduce the cost of starting from scratch each time it enters a new market.

Continue Reading

• Previous: How to Choose a Local Agent for Medical Device Registration in Thailand?
• Next: Why Is the Medical Device Registration Timeline in Thailand Extended?

Recommended Reading

• How should documentation be prepared for medical device registration in Malaysia?
• How should product classification be determined for medical device registration in Malaysia?
• How should the technical file be organized for medical device registration in Malaysia?
• How should labels and instructions for use be localized for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Back to FAQ Center

News and Insights

Contact AIMEILI

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary references.

Scope and applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal advice.